• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Hong Kong·Healthcare·0574.HK
Share

Pa Shun International Holdings Limited Stocks

HK$ 0.02Last Updated 27.07.2026

Issuer Rating

2/7
Performance

Modest

Risk

High

Recommendation

Sell

Market Cap

HK$ 4.57M

HK$ 0.02
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Pa Shun International Holdings Limited, an investment holding company, engages in the pharmaceutical distribution and manufacturing businesses in the People's Republic of China. The company sells pharmaceutical products to wholesalers, hospitals, and other medical institutions in rural areas. It also sells pharmaceutical products manufactured by the company. The company was formerly known as Pa Shun Pharmaceutical International Holdings Limited and changed its name to Pa Shun International Holdings Limited in June 2017. The company was incorporated in 2011 and is headquartered in Wan Chai, Hong Kong. Pa Shun International Holdings Limited operates as a subsidiary of Praise Treasure Limited.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is overvalued on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

05.10.2026 19:09

Oil exports from the Middle East exceeded pre-war levels in September

05.10.2026 18:48

Goldman and UBS recommended selling Hermès shares. The stock was among the top performers in the luxury sector.

05.10.2026 17:50

Citi upgrades Harley-Davidson to 'buy', raises TP on 'intriguing' turnaround story

05.10.2026 17:36

Over the past two years, billionaires with a combined net worth of $160 billion have left Britain. That's more than the total net worth of those who remained.

05.10.2026 16:59

Bloomberg: Tech billionaires now account for 36% of wealth of world's richest people

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026